Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James G Phillips

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
ACS Medicinal Chemistry Letters|December 21, 2016
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D InhibitorsChao-Yie Yang, James G Phillips, Jeanne A Stuckey, et al.
Oncotarget|February 25, 2016
The essential role of methylthioadenosine phosphorylase in prostate cancerGaia Bistulfi, Hayley C Affronti, Barbara A Foster, et al.
Neuropharmacology|March 6, 2007
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonistLindsay B Hough, Julia W Nalwalk, James G Phillips, et al.
Cancer Research|May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple MyelomaSergei Vatolin, James G Phillips, Babal K Jha, et al.
Pain|February 15, 2011
Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesicLindsay B Hough, Julia W Nalwalk, Jun Yang, et al.
Cancers|June 2, 2021
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple MyelomaMetis Hasipek, Dale Grabowski, Yihong Guan, et al.
Blood Cancer Discovery|March 8, 2021
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid NeoplasmsYihong Guan, Anand D Tiwari, James G Phillips, et al.
Nature Communications|January 9, 2020
Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapyHayley C Affronti, Aryn M Rowsam, Anthony J Pellerite, et al.
Haematologica|May 24, 2015
BRCC3 mutations in myeloid neoplasmsDayong Huang, Yasunobu Nagata, Vera Grossmann, et al.
Cancer Cell|April 30, 2015
Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsChantana Polprasert, Isabell Schulze, Mikkael A Sekeres, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
ACS Medicinal Chemistry Letters|December 21, 2016
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D InhibitorsChao-Yie Yang, James G Phillips, Jeanne A Stuckey, et al.
Oncotarget|February 25, 2016
The essential role of methylthioadenosine phosphorylase in prostate cancerGaia Bistulfi, Hayley C Affronti, Barbara A Foster, et al.
Neuropharmacology|March 6, 2007
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonistLindsay B Hough, Julia W Nalwalk, James G Phillips, et al.
Cancer Research|May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple MyelomaSergei Vatolin, James G Phillips, Babal K Jha, et al.
Pain|February 15, 2011
Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesicLindsay B Hough, Julia W Nalwalk, Jun Yang, et al.
Cancers|June 2, 2021
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple MyelomaMetis Hasipek, Dale Grabowski, Yihong Guan, et al.
Blood Cancer Discovery|March 8, 2021
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid NeoplasmsYihong Guan, Anand D Tiwari, James G Phillips, et al.
Nature Communications|January 9, 2020
Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapyHayley C Affronti, Aryn M Rowsam, Anthony J Pellerite, et al.
Haematologica|May 24, 2015
BRCC3 mutations in myeloid neoplasmsDayong Huang, Yasunobu Nagata, Vera Grossmann, et al.
Cancer Cell|April 30, 2015
Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsChantana Polprasert, Isabell Schulze, Mikkael A Sekeres, et al.
Pageof 6